Targeted treatment for fragile X syndrome: results of a randomized controlled phase II trial of arbaclofen

被引：0
|
作者：
Hagerman, Randi [1 ,2 ]
Rathmell, Barbara [3 ]
Wang, Lulu [1 ,2 ]
Carpenter, Randy [3 ]
Wang, Paul [3 ]
Berry-Kravis, Elizabeth [4 ]
机构：
[1] UC Davis Med Ctr, MIND Inst, Sacramento, CA USA
[2] UC Davis Med Ctr, Dept Pediat, Sacramento, CA USA
[3] Seaside Therapeut, Boston, MA USA
[4] Rush Univ, Med Ctr, Dept Neurol, Chicago, IL 60612 USA
来源：
JOURNAL OF INTELLECTUAL DISABILITY RESEARCH | 2010年 / 54卷
关键词：
fragile X syndrome; targeted treatments; GABA; arbaclofen;
D O I：
暂无
中图分类号：
G76 [特殊教育];
学科分类号：
040109 ;
摘要：
引用
收藏
页码：884 / 884
页数：1
相关论文
共 50 条
  • [21] A Randomized Double-Blind, Placebo-Controlled Trial of Minocycline in Children and Adolescents with Fragile X Syndrome
    Leigh, Mary Jacena S.
    Nguyen, Danh V.
    Mu, Yi
    Winarni, Tri I.
    Schneider, Andrea
    Chechi, Tasleem
    Polussa, Jonathan
    Doucet, Paul
    Tassone, Flora
    Rivera, Susan M.
    Hessl, David
    Hagerman, Randi J.
    JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS, 2013, 34 (03) : 147 - 155
  • [22] The quest for targeted therapy in fragile X syndrome
    Zeidler, Shimriet
    Hukema, Renate K.
    Willemsen, Rob
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2015, 19 (10) : 1277 - 1281
  • [23] New Targeted Treatments for Fragile X Syndrome
    Protic, Dragana
    Salcedo-Arellano, Maria J.
    Dy, Jeanne Barbara
    Potter, Laura A.
    Hagerman, Randi J.
    CURRENT PEDIATRIC REVIEWS, 2019, 15 (04) : 251 - 258
  • [24] Results from a Double-Blind, Randomized, Placebo-Controlled, Single-Dose, Crossover Trial of Lovastatin or Minocycline in Fragile X Syndrome
    Mckinney, Walker S.
    Schmitt, Lauren M.
    De Stefano, Lisa A.
    Ethridge, Lauren
    Norris, Jordan E.
    Horn, Paul S.
    Dauterman, Shelby
    Rosselot, Hilary
    Pedapati, Ernest V.
    Reisinger, Debra L.
    Dominick, Kelli C.
    Shaffer, Rebecca C.
    Chin, Danielle
    Friedman, Nicole R.
    Hong, Michael
    Sweeney, John A.
    Erickson, Craig
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2024, : 211 - 221
  • [25] Clinical Development of Targeted Fragile X Syndrome Treatments: An Industry Perspective
    Lee, Anna W.
    Ventola, Pamela
    Budimirovic, Dejan
    Berry-Kravis, Elizabeth
    Visootsak, Jeannie
    BRAIN SCIENCES, 2018, 8 (12):
  • [26] Arbaclofen extended-release tablets for spasticity in multiple sclerosis: randomized, controlled clinical trial
    Okuda, Darin T.
    Kantor, Daniel
    Jaros, Mark
    deVries, Tina
    Hunter, Samuel
    BRAIN COMMUNICATIONS, 2022, 4 (06)
  • [27] Metformin treatment in young children with fragile X syndrome
    Biag, Hazel Maridith B.
    Potter, Laura A.
    Wilkins, Victoria
    Afzal, Sumra
    Rosvall, Alexis
    Salcedo-Arellano, Maria Jimena
    Rajaratnam, Akash
    Manzano-Nunez, Ramiro
    Schneider, Andrea
    Tassone, Flora
    Rivera, Susan M.
    Hagerman, Randi J.
    MOLECULAR GENETICS & GENOMIC MEDICINE, 2019, 7 (11):
  • [28] Psychometric Study of the Aberrant Behavior Checklist in Fragile X Syndrome and Implications for Targeted Treatment
    Sansone, Stephanie M.
    Widaman, Keith F.
    Hall, Scott S.
    Reiss, Allan L.
    Lightbody, Amy
    Kaufmann, Walter E.
    Berry-Kravis, Elizabeth
    Lachiewicz, Ave
    Brown, Elaine C.
    Hessl, David
    JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS, 2012, 42 (07) : 1377 - 1392
  • [29] Psychometric Study of the Aberrant Behavior Checklist in Fragile X Syndrome and Implications for Targeted Treatment
    Stephanie M. Sansone
    Keith F. Widaman
    Scott S. Hall
    Allan L. Reiss
    Amy Lightbody
    Walter E. Kaufmann
    Elizabeth Berry-Kravis
    Ave Lachiewicz
    Elaine C. Brown
    David Hessl
    Journal of Autism and Developmental Disorders, 2012, 42 : 1377 - 1392
  • [30] Modulation of the GABAergic pathway for the treatment of fragile X syndrome
    Lozano, Reymundo
    Hare, Emma B.
    Hagerman, Randi J.
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2014, 10 : 1769 - 1778
12345